Key Drivers
- High profitability
- Strong free cashflow
- Large intangibles
AIAI Summary
Abbott has shifted from a steady device compounder to a leverage‑sensitive consolidator—its premium valuation now depends on timely Libre recall resolution and rapid, successful integration of Exact Sciences to justify the added debt and intangible risk, with misses likely to produce outsized downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Strong free cashflow
- •Large intangibles
Abbott delivers durable high margins, strong free cash flow and moderate leverage but carries premium valuation, low asset turnover and large intangibles that increase downside risk.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Near-oversold RSI
- •Testing support lows
Over the last month ABT has slipped from a February range into a short-term downtrend—about a 6% decline, trading below the last-month SMA with RSI near 29 and testing recent lows in the high-$108s.
~6% decline since 2026-02-20 shifting from
Sentiment & News
Key News Insights:
- •Institutional buying
- •Devices growth
- •Nutrition weakness
Analysts' bullish ratings and large institutional buys highlight confidence in Abbott's Devices/Diagnostics strength and the Exact Sciences deal, but Nutrition and execution issues pose near-term risks.
Overall positive medium‑term catalyst if execution improves, though expect near‑term volatility tied to Nutrition performance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings